An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer

Dilara Sahin; Natalia Arenas-Ramirez; Matthias Rath; Ufuk Karakus; Monika Hümbelin; Merel van Gogh; Lubor Borsig; Onur Boyman

doi:10.1038/s41467-020-20220-1

Nature Communications (Dec 2020)

An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer

Dilara Sahin,
Natalia Arenas-Ramirez,
Matthias Rath,
Ufuk Karakus,
Monika Hümbelin,
Merel van Gogh,
Lubor Borsig,
Onur Boyman

Affiliations

Dilara Sahin: Department of Immunology, University Hospital Zurich
Natalia Arenas-Ramirez: Department of Immunology, University Hospital Zurich
Matthias Rath: Department of Immunology, University Hospital Zurich
Ufuk Karakus: Department of Immunology, University Hospital Zurich
Monika Hümbelin: Department of Immunology, University Hospital Zurich
Merel van Gogh: Institute of Physiology, University of Zurich
Lubor Borsig: Institute of Physiology, University of Zurich
Onur Boyman: Department of Immunology, University Hospital Zurich

DOI: https://doi.org/10.1038/s41467-020-20220-1
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

IL-2/anti-IL-2 complexes have been proposed to curtail the severe adverse effects associated with IL-2 immunotherapy. Here, the authors, by integrating unmutated human IL-2 in the antigen binding groove of an anti-IL-2 monoclonal antibody, generate a CD122-biased fusion protein that prevents binding of IL-2 to CD25 and promotes anti-tumor immune response in several preclinical metastatic cancer models.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal